Bryostatin-23

Nov. 10, 2021 13:00 UTC WOBURN, Mass.--(BUSINESS WIRE)-- Aphios Corporation today announced that it has been granted Chinese Patent No. 201811111996.8 by China National Intellectual Property Administration on October 26, 2021. The patent entitled, “Bryoid Compositions, Methods of Making and Use Thereof,” covers novel composition of matter of the novel Bryoid, Bryostatin-23 and use for the treatment of Alzheimer’s disease and other neurodegenerative diseases, virus latency diseases such as HIV and Herpes, cancers and glaucoma. According to Dr. Trevor P. Castor, President and CEO, Aphios Corporation: “This novel Bryoid, Bryostatin-23, is a highly potent nanomolar activator of α-secretase activity in neuroblastoma cell models, being more effective than the canonical Bryostatin-1 at increasing activity of all protein kinase C (PKC) isoforms, particularly the novel PKC isoforms, delta and epsilon. It thus has a higher therapeutic efficacy than Bryostatin-1.” About Aphios Corporation: Aphios Corporation ( ) is a green biotechnology company developing enabling technology platforms for improving drug discovery, manufacturing, delivery and safety, and enhanced natural therapeutics for health maintenance and disease prevention, and treatment of Alzheimer’s disease.